Tricks and pitfalls regarding the hemodynamics of patients undergoing non-transplantation surgery for heart failure

Minerva Anestesiologica

Volumn 74, Issue 12, 2008, Pages 715-725

  Crescenzi, G ^a   Pappalardo, F ^a   Rosica, C ^a   Gonfalini, M ^a   Landoni, G ^a   Zangrillo, A ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Anesthetics, general; Cardiac surgical procedures; Heart, physiology; Myocardial contraction; Postoperative complications; Pulmonary wedge pressure; Vascular resistance

Indexed keywords

ADRENALIN; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; DESFLURANE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; INOTROPIC AGENT; LEVOSIMENDAN; METHYLENE BLUE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE III INHIBITOR; SEVOFLURANE; VASODILATOR AGENT;

AORTA BALLOON; CARDIAC RESYNCHRONIZATION THERAPY; CENTRAL VENOUS PRESSURE; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DIASTOLIC HEART FAILURE; HEART AFTERLOAD; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT ATRIUM PRESSURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE REVASCULARIZATION; HEART PRELOAD; HEART RIGHT VENTRICLE FAILURE; HEART VALVE SURGERY; HEMODYNAMIC MONITORING; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTENSIVE CARE; LUNG ARTERY PRESSURE; LUNG WEDGE PRESSURE; MITRAL VALVE REGURGITATION; PATIENT MONITORING; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; PULMONARY ARTERY CATHETER; REVIEW; SURGICAL PATIENT; SURGICAL RISK; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC DYSFUNCTION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; VASOPLEGIC SYNDROME;

ANESTHESIA; CARDIAC SURGICAL PROCEDURES; HEART FAILURE; HEMODYNAMICS; HUMANS;

EID: 59849098847     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Baig MK, Mahon N, McKenna WJ, Caforio AL, Bonow RO, Francis GS et al. The pathophysiology of advanced heart failure. Am Heart J 1998;135:s216-30.
2. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999;100:999-1008.
3. Barry WH, Gilbert EM. How do β-blockers improve ventricular function in patients with congestive heart failure? Circulation 2003; 107:2395-7.
4. Braunwald E. The Denolin lecture. Congestive heart failure: a half century perspective. Eur Heart J 2001;22:825-36.
5. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000;101:2981-8.
6. Miyata S, Minobe WA, Bristow MR, Leinwand LA. Myosin heavy chain isoform expression in the failing and non failing human heart. Circ Res 2000;86:386-90.
7. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation 2000;102(20 Suppl 4):IV14-IV23.
8. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996;335:1182-9.
9. Khoynezhad A, Jalali Z, Tortolani AJ. Apoptosis: pathophysiology and therapeutic implications for the cardiac surgeon. Ann Thorac Surg 2004;78:1109-18.
10. Otsuji Y, Gilon D, Jiang L, He S, Leavitt M, Roy MJ et al. Restricted diastolic opening of the mitral leaflets in patients with left ventricular dysfunction: evidence for increased valve tethering. J Am Coll Cardiol 1998;32:398-404.
11. Buckberg GD. Congestive heart failure: treat the disease, not the symptom-Return to normalcy. J Thorac Cardiovasc Surg 2003;125:s41-s49.
12. Burkhoff D. New heart failure therapy: the shape of things to come? J Thorac Cardiovasc Surg 2003;125:s50-s52.
13. Schenk S, McCarthy PM, Starling RC, Hoercher KJ, Hail MD, Ootaki Y et al. Neurohormonal response to left ventricular reconstruction surgery in ischemic cardiomyopathy. J Thorac Cardiovasc Surgery 2004;128:38-43.
14. Vanoverschelde JL, Depré C, Gerber BL, Burgers M, Wijns W, Robert A et al. Time course of functional recovery after coronary artery bypass graft surgery in patients with chronic left ventricular ischemic dysfunction. Am J Cardiol 2000;85:1432-9.
15. Mickleborough LL, Carson S, Ivanov J. Repair of dyskinetic or akinetic left ventricular aneurysm: results obtained with modified linear closure. J Thorac Cardiovasc Surg 2001;121: 675-82.
16. Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 2005;45:381-7.
17. Griffin MJ, Hines RL. Management of perioperative ventricular dysfunction. J Cardiothorac Vasc Anesrh 2001;15:90-106.
18. Jneid H, Bolli R. Inotrope use at separation from cardiopulmonary bypass and the role of prebypass TEE. J Cardiothorac Vasc Anesth 2004;18:401-3.
19. Crescenzi G, Landoni G, Romano A, Boroli F, Giardina G, Bignami E et al. A propensity score analysis on the effect of eliminating cardiopulmonary bypass for coronary artery bypass grafting. Minerva Anestesiol 2007;73:135-41.
20. Landoni G, Pappalardo F, Calabrò MG, Boroli F, Sottocorna O, Aletti G et al. Myocardial necrosis biomarkers after different cardiac surgical operations. Minerva Anestesiol 2007;73:49-56.
21. Crivellari M, Landoni G, Belotti F, Cedrati V, Scandroglio AM, Boroli F et al. Multivessel off-pump coronary artery bypass grafting in a nonagenarian: anesthesiologic management. Minerva Anestesiol 2006;72:1001-5.
22. Gerli C, Mantovani L, Franco A, De Luca M, Bergonzi PC, Boroli F et al. Redo coronary artery bypass grafting on the beating heart and transfusion needs. Minerva Anestesiol 2006;72:985-93.
23. Zangrillo A, Gerli C, Landoni G, Sparicio D, Roberti A, Sottocorna O et al. Anesthesiological management and outcome of 100 "beating heart" coronary artery bypass grafting. Minerva Anestesiol 2006;72:827-39.
24. Chierego M, Verdant C, De Backer D. Microcirculatory alterations in critically ill patients. Minerva Anestesiol 2006;72:199-205.
25. Stucchi R, Poli G, Fumagalli R. Hemodynamic monitoring in ICU. Minerva Anestesiol 2006;72:483-7.
26. Dalen JE. The pulmonary artery catheter-friend, foe, or accomplice? JAMA 2001;286:348-50.
27. Sandham JD, Hull RD, Brant RF, Knox L, Pineo GF, Doig CJ et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003;348:5-14.
28. Richard C, Warszawski J, Anguel N, Deye N, Combes A, Barnoud D et al. Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2003;290:2713-20.
29. Stewart RD, Psyhojos T, Lahey SJ, Levitsky S, Campus CT. Central venous catheter use in low-risk coronary artery bypass grafting. Ann Thorac Surg 1998;66:1306-11.
30. Tuman KJ, McCarthy RJ, Spiess BD, DaValle M, Hompland SJ, Dabir R et al. Effect of pulmonary artery catheterization on outcome in patients undergoing coronary artery surgery. Anesthesiology 1989;70:199-206.
31. Pulmonary Artery Catheter Consensus conference: consensus statement. Crit Care Med. 1997;25:910-25.
32. Ramsey SD, Saint S, Sullivan SD, Dey L, Kelley K, Bowdle A. Clinical and economic effects of pulmonary artery catheterization in nonemergent coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2000;14:113-8.
33. Ranucci M. Which cardiac surgical patients can benefit from placement of a pulmonary artery catheter? Crit Care 2006;10 Suppl 3:S6.
34. Ranucci M, De Toffol B, Isgrò G, Romitti F, Conti D, Vicentini M. Hyperlactatemia during cardiopulmonary bypass: determinants and impact on postoperative outcome. Crit Care 2006;10:R167.
35. American Society of Anesthesiologists and Society of Cardiovascular Anesthesiologists Task Force on Transesophageal Echocardiography. Practice guidelines for preoperative transesophageal echocardiography. Anesthesiology 1996;84:986-1006.
36. Lennon MJ, Gibbs NM, Weightman WM, Leber J, Ee HC, Yusoff IF. Transesophageal echocardiography-related gastrointestinal complications in cardiac surgical patients. J Cardiothorac Vasc Anesth 2005;19:141-5.
37. Malouf JF, Enriquez-Sarano M, Pellikka PA, Oh JK, Bailey KR, Chandrasekaran K et al. Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications. J Am Coll Cardiol 2002;40:789-95.
38. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000;102:1718-23.
39. Ganter CC, Jakob SM, Takala J. Pulmonary capillary pressure. A review. Minerva Anestesiol 2006;72:21-36.
40. Bocchi EA, Bacal F, Auler Jùnior JO, Carmone MJ, Bellotti G, Pileggi F. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure. Am J Cardiol 1994;74:70-2.
41. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134:44-54.
42. Stobierska-Dzierzek B, Awad H, Michler RE. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 2001;38:923-31.
43. Kaul TK, Fields BL. Postoperative acute refractory right ventricular failure: incidence, pathogenesis, management and prognosis. Cardiovasc Surg 2000;8:1-9.
44. Fischer LG, Van Aken H, Burkle H. Management of pulmonary hypertension: physiological and pharmacological considerations for anesthesiologists. Anesth Analg 2003;96:1603-16.
45. Haikala H, Pollesello P. Calcium sensitivity enhancers. IDrugs 2000;3:1199-205.
46. Steel A, Bihari D. Choice of catecholamine: does it matter? Curr Opin Crit Care 2000;6:347-53.
47. Field ML, Rengarajan A, Khan O, Spyt T, Richens D. Preoperative intra aortic balloon pumps in patients undergoing coronary artery bypass grafting. Cochrane Database Syst Rev 2007;(1):CD004472.
48. Remme WJ, Swedberg K; Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60. Erratum in: Eur Heart J 2001;22:2217-8.
49. Flynn MJ, McComb JM, Dark JH. Temporary left ventricular pacing improves haemodynamic performance in patients requiring epicardial pacing post cardiac surgery. Eur J Cardiothorac Surg 2005;28:250-3.
50. Thys DM, Dauchot P, Hillel Z. Advances in cardiovascular physiology. In: Kaplan JA, editor. Cardiac anesthesia. Philadelphia: WB Saunders Company; 1999.p.217-40.
51. Levin RL, Degrange MA, Bruno GF, Del Mazo CD, Taborda DJ, Griotti JJ et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004;77:496-9.
52. Özal E, Kuralay E, Yildirim V, Kilic S, Bolcal C, Kucukarslan N et al. Preoperative methylene blue administration in patients at high risk for vasoplegic sindrome during cardiac surgery. Ann Thorac Surg 2005;79:1615-9.
53. Sparicio D, Landoni G, Zangrillo A. Angsotensin-converting enzyme inhibitors predispose to hypotension refractory to norepinephrine but responsive to methylene blue. J Thorac Cardiovasc Surg 2004;127:608.
54. Sparicio D, Landoni G, Pappalardo F, Crivellari M, Cerchierini E, Marino G et al. Methylene blue for lithium-induced refractory hypotension in off-pump coronary artery bypass graft: report of two cases. J Thorac Cardiovasc Surg 2004;127:592-3.
55. Cremer J, Martin M, Redl H, Bahrami S, Abraham C, Graeter T et al. Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996;61:1714-20.
56. Mekontso-Dessap A, Houel R, Soustelle C, Kirsch M, Thébert D, Loisance DY. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thotac Surg 2001;71:1428-32.
57. Leyh RG, Kofidis T, Struber M, Fischer S, Knobloch K, Wachsmann B et al. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J Thorac Cardiovasc Surg 2003;125:1426-31.
58. Reich DL, Moskowitz DM, Kaplan JA. Hemodynamic monitoring. In: Kaplan JA, editor. Cardiac anesthesia. Philadelphia: WB Saunders Company; 1999.p.321-58.
59. Smith MD. Left ventricular diastolic function. In: Otto C, editor. The practice of clinical echocardiography. Philadelphia: WB Saunders Company; 2002.p.113-40.
60. How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J 1998;19:990-1003.
61. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317-27.
62. Angeja BG, Grossman W. Evaluation and management of diastolic heart failure. Circulation 2003;107:659-63.
63. van den Berghe G, Wouters P, Weekets F, Verwaest C, Bruyninckx F, Schetz M et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67.
64. Murkin JM. Pro: tight intraoperative glucose control improves outcome in cardiovascular surgery. J Cardiothorac Vasc Anesth 2000;4:475-8.
65. Karkouti K, Beattie WS, Wijeysundera DN, Rao V, Chan C, Dattilo KM et al. Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery. J Thorac Cardiovasc Surg 2005;129:391-400.
66. Landoni G, Biondi-Zoccai GG, Zangrillo A, Bignami E, D'Avolio S, Marchetti C et al. Desflurane and sevoflurane in cardiac surgery: a meta-analysis of randomized clinical trials. J Cardiothorac Vasc Anesth 2007;21:502-11.
67. Tritapepe L, Landoni G, Guarracino F, Pompei F, Crivellari M, Maselli D et al. Cardiac protection by volatile anaesthetics: a multicentre randomized controlled study in patients undergoing coronar'y artery bypass grafting with cardiopulmonary bypass. Eur J Anaesthesiol 2007;24:323-31.
68. Guarracino F, Landoni G, Tritapepe L, Pompei F, Leoni A, Aletti G et al. Myocardial damage prevented by volatile anesthetics: a multicenter randomized controlled study. J Cardiothorac Vasc Anesth 2006;20:477-83.
69. Landoni G, Calabrò MG, Marchetti C, Bignami E, Scandroglio AM, Dedola E et al. Desflurane versus propofol in patients undergoing mitral valve surgery. J Cardiothorac Vasc Anesth 2007; 21:672-7.
70. Cromheecke S, Pepermans V, Hendrickx E, Lorsomradee S, Ten Broecke PW, Stockman BA et al. Cardioprotective properties of sevoflurane in patients undergoing aortic valve replacement with cardiopulmonary bypass. Anesth Analg 2006;103:289-96.
71. Landoni G, Biondi-Zoccai GG, Tumlin JA, Bove T, De Luca M, Calabro MG et al. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis 2007;49:56-68.
72. Landoni G, Biondi-Zoccai GG, Marino G, BoveT, Fochi O, Maj G et al. Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2008;22:27-33.
73. Roasio A, Lobreglio R, Santin A, Landoni G, Verdecchia C. Fenoldopam reduces the incidence of renal replacement therapy after cardiac surgery. J Cardiothorac Vasc Anesth 2008;22:23-6.
74. Cogliati AA, Vellutini R, Nardini A, Urovi S, Hamdan M, Landoni G et al. Fenoldopam infusion for renal protection in high risk cardiac surgery patients: a randomized clinical study. J Cardiothorac Vasc Anesth 2007;21:847-50.